



(11) **EP 2 650 293 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 71

(51) Int Cl.:
C07D 487/04 (2006.01) **A61K 31/53** (2006.01)
A61P 35/00 (2006.01) **A61P 35/02** (2006.01)

(48) Corrigendum issued on:
25.12.2013 Bulletin 2013/52

(86) International application number:
PCT/CN2011/002052

(43) Date of publication:
16.10.2013 Bulletin 2013/42

(87) International publication number:
WO 2012/075683 (14.06.2012 Gazette 2012/24)

(21) Application number: **11846471.8**

(22) Date of filing: **08.12.2011**

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **08.12.2010 CN 201010579221**

(71) Applicant: **Shanghai Institute of Materia Medica,
Chinese Academy of Sciences
Shanghai 201203 (CN)**

(72) Inventors:
• **DUAN, Wenhui**
Pudong
Shanghai 201203 (CN)
• **GENG, Meiyu**
Pudong
Shanghai 201203 (CN)
• **CHEN, Fang**
Pudong
Shanghai 201203 (CN)


- **AI, Jing**
Pudong
Shanghai 201203 (CN)
- **CHEN, Yi**
Pudong
Shanghai 201203 (CN)
- **ZHAN, Zhengsheng**
Pudong
Shanghai 201203 (CN)
- **LV, Yongcong**
Pudong
Shanghai 201203 (CN)
- **WANG, Ying**
Pudong
Shanghai 201203 (CN)
- **DING, Jian**
Pudong
Shanghai 201203 (CN)

(74) Representative: **HOFFMANN EITLE**
Patent- und Rechtsanwälte
Arabellastrasse 4
81925 München (DE)


(54) **[1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF**

(57) The present invention relates to a structurally novel [1,2,4]triazolo[4,3-b][1,2,4]triazine compounds represented by formula (I) or formula (II), pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and also relates to a preparation method of the compounds, a pharmaceutical composition comprising a therapeutically effective amount of the compounds, as well as the use thereof as protein tyrosine kinase inhibitors, particularly as c-Met inhibitors, in the preparation of medicaments for the prevention and/or treatment of diseases associated with c-Met abnormality.

EP 2 650 293 A8



(I)



(II)